<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120757</url>
  </required_header>
  <id_info>
    <org_study_id>2004-002002-30</org_study_id>
    <secondary_id>ANRS120 Fosivir</secondary_id>
    <nct_id>NCT00120757</nct_id>
  </id_info>
  <brief_title>Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)</brief_title>
  <official_title>Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteopenia and osteoporosis are being described more frequently in people with HIV infection.&#xD;
      This study will test the efficacy of alendronate in comparison with a placebo after 2 years,&#xD;
      in people with primary osteoporosis. People will receive the recommended adequate intake of&#xD;
      calcium and vitamin D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of this trial are:&#xD;
&#xD;
        -  To study the efficacy of alendronate in HIV-associated osteoporosis&#xD;
&#xD;
        -  To measure the prevalence of osteoporosis in HIV patients and to detect risk factors in&#xD;
           a large cohort of HIV patients from the screening phase&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of variation of lumbar BMD on DEXA scan at month 24 versus month 0 for patients included with lumbar osteoporosis (femoral for those included with only femoral osteoporosis)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of variation of femoral T-score between M0 and M24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of variation of lumbar and femoral T score between M0 and M12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of bone metabolism markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of fractures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of alendronate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the prevalence of osteopenia and osteoporosis in HIV-infected men and women</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the evolution of osteoporosis in HIV-infected men and women receiving calcium and vitamin D to define risk factors for osteoporosis in HIV-infected persons</measure>
  </secondary_outcome>
  <enrollment>140</enrollment>
  <condition>Osteoporosis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-pregnant&#xD;
&#xD;
          -  Non menopausal women&#xD;
&#xD;
          -  Total femur BMD below -2.5 SD (T score) or lumbar spine BMD below -2.5 SD (T score) or&#xD;
             BMD below -1 associated with a vertebral osteoporotic fracture (diminution of&#xD;
             vertebral height over 20%)&#xD;
&#xD;
          -  HIV infection known for at least 5 years&#xD;
&#xD;
          -  CD4 cell count over 50/mm3&#xD;
&#xD;
          -  Karnofsky score over or equal to 70&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Osteoporosis resulting from a cause other than HIV: vitamin D deficiency (in that&#xD;
             case, after receiving high-dose calcium and vitamin D for 1 month, patients will be&#xD;
             randomized without a new screening), renal failure, heart failure (NHYA class III or&#xD;
             IV), treatment with glucocorticoid at a dose over or equal to 0.5mg/kg/d for 15 days&#xD;
             or more at time of inclusion or during the previous 6 months; thyroid or other&#xD;
             endocrine disease if untreated for more than 6 months; hypercalciuria&#xD;
&#xD;
          -  Testosterone below normal if treatment is hormonal&#xD;
&#xD;
          -  BMI below or equal to 18&#xD;
&#xD;
          -  Severe lung failure&#xD;
&#xD;
          -  Chronic alcohol intoxication&#xD;
&#xD;
          -  Ongoing opportunistic infection&#xD;
&#xD;
          -  Gastric ulcer of disease interfering with oesophageal motility in the previous 3&#xD;
             months&#xD;
&#xD;
          -  History of treatment for osteoporosis&#xD;
&#xD;
          -  History of malignancy in the previous 5 years (except skin cancer and Kaposi)&#xD;
&#xD;
          -  Cytotoxic chemotherapy or cytokine therapy&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Rozenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Pitie-Salpetriere Paris service de Rhumatologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Costagliola</last_name>
    <role>Study Chair</role>
    <affiliation>Inserm U720</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Medecine Interne hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009 cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Necker service des Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>July 11, 2005</study_first_submitted>
  <study_first_submitted_qc>July 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2005</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

